Literature DB >> 25011996

Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma.

Matthew J Ahearne1, Kaljit Bhuller, Roger Hew, Hazem Ibrahim, Kikkeri Naresh, Simon D Wagner.   

Abstract

The role of the microenvironment in high-grade lymphoma is not well defined. In this report, we employ immunohistochemistry to characterise programmed death-1 (PD-1/CD279) and FoxP3 expression in 70 cases of diffuse large B-cell lymphoma (DLBCL). PD-1 is a surface marker characteristic of follicular helper T-cells whilst FoxP3 is characteristic of Tregs. We demonstrate variable infiltration with CD4(+) T-cells (<10 to >50 % of all lymph node cells) and PD-1(hi) cells (0.1 to 1.5 % of all cells). CD4(+) T-cells can be distributed in clusters or more diffusely and PD-1(hi) cells, but not FoxP3(+) cells, are found in rosettes around lymphoma cells. Cases with high CD4(+) T-cell numbers tended to have higher numbers of both PD-1(hi) and FoxP3(+) cells. Cases with total CD4(+) T-cell, PD-1(hi) and FoxP3(+) numbers above the median associate with better clinical outcome. Overall, we demonstrate that infiltration by CD4(+) T-cells, including both FoxP3(+) and PD-1(hi) subsets, correlates with prognosis in DLBCL. In distinction to previous reported series, patients (91 %) were treated with rituximab-containing regimens, suggesting that the effects of CD4+ T-cell infiltration are maintained in the rituximab era. This work suggests that determinants of total CD4(+) T-cell infiltration, either molecular characteristics of the lymphoma or the patients' immune system, and not individual T-cell subsets, correlate with clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25011996     DOI: 10.1007/s00428-014-1615-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  41 in total

1.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.

Authors:  Margaret A Shipp; Ken N Ross; Pablo Tamayo; Andrew P Weng; Jeffery L Kutok; Ricardo C T Aguiar; Michelle Gaasenbeek; Michael Angelo; Michael Reich; Geraldine S Pinkus; Tane S Ray; Margaret A Koval; Kim W Last; Andrew Norton; T Andrew Lister; Jill Mesirov; Donna S Neuberg; Eric S Lander; Jon C Aster; Todd R Golub
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

2.  Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.

Authors:  Ben Youngblood; Kenneth J Oestreich; Sang-Jun Ha; Jaikumar Duraiswamy; Rama S Akondy; Erin E West; Zhengyu Wei; Peiyuan Lu; James W Austin; James L Riley; Jeremy M Boss; Rafi Ahmed
Journal:  Immunity       Date:  2011-09-23       Impact factor: 31.745

3.  Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course.

Authors:  S M Lippman; C M Spier; T P Miller; D J Slymen; J A Rybski; T M Grogan
Journal:  Mod Pathol       Date:  1990-05       Impact factor: 7.842

4.  Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.

Authors:  S M Ansell; M Stenson; T M Habermann; D F Jelinek; T E Witzig
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

Review 5.  T-cell subsets in the germinal center.

Authors:  Roybel R Ramiscal; Carola G Vinuesa
Journal:  Immunol Rev       Date:  2013-03       Impact factor: 12.988

6.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

7.  Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages.

Authors:  Roza I Nurieva; Yeonseok Chung; Daehee Hwang; Xuexian O Yang; Hong Soon Kang; Li Ma; Yi-hong Wang; Stephanie S Watowich; Anton M Jetten; Qiang Tian; Chen Dong
Journal:  Immunity       Date:  2008-07-03       Impact factor: 31.745

8.  Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.

Authors:  Alexandar Tzankov; Cecile Meier; Petra Hirschmann; Philip Went; Stefano A Pileri; Stephan Dirnhofer
Journal:  Haematologica       Date:  2008-01-26       Impact factor: 9.941

9.  Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma.

Authors:  Sajjan Mittal; Neil A Marshall; Linda Duncan; Dominic J Culligan; Robert N Barker; Mark A Vickers
Journal:  Blood       Date:  2008-02-27       Impact factor: 22.113

10.  Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring.

Authors:  Anthony E Rizzardi; Arthur T Johnson; Rachel Isaksson Vogel; Stefan E Pambuccian; Jonathan Henriksen; Amy Pn Skubitz; Gregory J Metzger; Stephen C Schmechel
Journal:  Diagn Pathol       Date:  2012-06-20       Impact factor: 2.644

View more
  27 in total

1.  Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry.

Authors:  Janice S Ahn; Ali Al-Habib; Jeffrey A Vos; Aliyah R Sohani; Oralia Barboza-Quintana; Juan P Flores; Sijin Wen; Flavia G Rosado
Journal:  Ann Clin Lab Sci       Date:  2020-03       Impact factor: 1.256

Review 2.  Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.

Authors:  Lorenzo Falchi
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 3.  Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?

Authors:  Andrew Davies
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.

Authors:  Wook Youn Kim; Ho Young Jung; Soo Jeong Nam; Tae Min Kim; Dae Seog Heo; Chul-Woo Kim; Yoon Kyung Jeon
Journal:  Virchows Arch       Date:  2016-09-05       Impact factor: 4.064

Review 5.  PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.

Authors:  Aaron Goodman; Sandip P Patel; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2016-11-02       Impact factor: 66.675

Review 6.  Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

Authors:  Fabienne McClanahan; Thomas G Sharp; John G Gribben
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

7.  Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection.

Authors:  Shohei Eto; Kozo Yoshikawa; Masaaki Nishi; Jun Higashijima; Takuya Tokunaga; Toshihiro Nakao; Hideya Kashihara; Chie Takasu; Takashi Iwata; Mitsuo Shimada
Journal:  Gastric Cancer       Date:  2015-07-26       Impact factor: 7.370

8.  Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.

Authors:  Junichi Kiyasu; Hiroaki Miyoshi; Akie Hirata; Fumiko Arakawa; Ayako Ichikawa; Daisuke Niino; Yasuo Sugita; Yuji Yufu; Ilseung Choi; Yasunobu Abe; Naokuni Uike; Koji Nagafuji; Takashi Okamura; Koichi Akashi; Ryoichi Takayanagi; Motoaki Shiratsuchi; Koichi Ohshima
Journal:  Blood       Date:  2015-08-03       Impact factor: 22.113

9.  Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8+ T-cells despite immune checkpoint signaling.

Authors:  Adam M Greenbaum; Jonathan R Fromm; Ajay K Gopal; A McGarry Houghton
Journal:  Blood Res       Date:  2022-05-13

Review 10.  PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.

Authors:  Zijun Y Xu-Monette; Jianfeng Zhou; Ken H Young
Journal:  Blood       Date:  2017-11-08       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.